Introduction
============

Venous thromboembolism (VTE) represents a spectrum of diseases that include deep vein thrombosis, central venous catheters associated thrombosis (CVC-thrombosis), and pulmonary embolism (PE). Both clinically symptomatic and asymptomatic episodes of VTE are common in hospitalized patients ([@b62]), and are associated with high mortality ([@b130]; [@b5]; [@b123]; [@b67]). Autopsy studies have shown that approximately 10% of all inpatients deaths are due to PE, but only a small proportion of PE are suspected before death ([@b165]; [@b219]). Until the mid 90s, most studies focused on surgical patients, given their high incidence of VTE. As a consequence, the notion about the need for VTE prophylaxis in surgical populations gained acceptance. More recently, randomized controlled trials have highlighted the fact that the risk of VTE in patients with medical conditions is similar to that of some surgical patients ([@b15]; [@b73]; [@b115]; [@b187]; [@b106]; [@b116]). Additionally, some epidemiological studies have demonstrated that more than half of patients who develop symptomatic VTE have medical, not surgical conditions ([@b62]). In the registry RIETE ([@b150]), only 28% of acutely ill medical patients with decreased mobility had received prophylaxis, while 67% of surgical patients did. During the follow-up of these patients, both PE and fatal bleedings were more common in medical patients, underlying the need for adequate prophylactic regimens in this particular subset of patients. Therefore, the analysis of the importance of risk factors in hospitalized medical patients is crucial to define the risk-benefit of VTE prophylaxis utilization. A systematic review of risk factors for VTE was performed, evaluating the current evidence about the factors that could justify the use of VTE prophylaxis in this population. The evidence about the effectiveness of VTE prophylaxis in these specific groups was also reviewed, and evidence-based recommendations were incorporated into an easy-to-use risk-assessment algorithm for VTE.

Methods
=======

Literature search
-----------------

A computer-based literature search was performed independently by two investigators to identify studies evaluating the following conditions as risk factors for thrombosis in acutely ill medical patients: active rheumatologic diseases (ARD) and inflammatory bowel disease (IBD), acute myocardial infarction (AMI), admission to ICU, age, cancer, chemotherapy and hormonotherapy, central venous catheters (CVC), cerebral vascular accident (CVA), congestive heart failure (CHF), diabetes, hormonal contraception (HC) and hormonal replacement therapy (HRT), hypertension, infections, nephrotic syndrome, obesity, paresis and/or paralysis of the lower extremities, peripheral vascular disease, pregnancy and puerperium, previous VTE, reduced mobility, respiratory diseases (eg, chronic obstructive pulmonary disease \[COPD\], respiratory insufficiency, and respiratory infections), tobacco use, and thrombophilias. We also evaluated the efficacy of methods of VTE prophylaxis in acutely ill medical patients, including low dose unfractionated heparin (LDUH), low molecular weight heparins (LMWH), and mechanical methods of prophylaxis. We searched the English language and non-English language literature by using MEDLINE, LILACS databases, and the Cochrane Central Register of Controlled Trials from the earliest searchable dates through August 2004. Annals of important meetings were also searched for abstracts from 1998 onwards. The reference lists of published reviews were also evaluated.

Data collection
---------------

Inclusion criteria for the systematic review were established before the literature search. We included randomized-controlled trials, cohorts, and case-control studies with at least 10 subjects evaluating risk factors or efficacy of prophylactic methods for VTE. Two authors read all retrieved studies and made the final decision on which studies met the inclusion criteria. All data were abstracted independently and in duplicate by two of the authors using a standardized data collection form. Discrepancies in the data abstracted were resolved by consensus among the authors and the working committee.

Levels of evidence
------------------

The level of evidence of each study was classified based on the American Heart Association, American College of Cardiology, and European Society of Cardiology (AHA/ACC/ESC) guidelines for the management of patients with supraventricular arrhythmias ([@b19]). These criteria were adapted to allow evaluation of studies about efficacy of methods of VTE prophylaxis and risk factors for VTE. [Tables 1A and 1B](#tbl1){ref-type="table"} show the levels of evidence and [Table 2](#tbl2){ref-type="table"} shows the strength of recommendations.

###### 

Classification of levels of evidence for the studies

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  1A\                     Studies about risk factors
  Level of evidence       
  ----------------------- -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  A                       Evidence derived from several RCTs, cohorts using screening methods for VTE and/or case-control studies suggesting that the risk factor is directly associated with the disease.

  B                       Evidence derives from a limited number of RCTs, cohorts and/or case-control studies, or with conflicting information and/or divergence of opinion that the risk factor is directly associated with the disease.

  C                       Evidence from RCTs, cohorts and/or case-control studies, that the risk factor is NOT directly associated with the disease.

                          

  **1B**\                 **Studies about treatment, prevention or etiology**
  **Level of evidence**   

                          

  A                       Evidence derived from RCTs.

  B                       Evidence derived from RCTs with methodologic flaws, or published only as abstracts, or nonrandomized studies, or observational registries.

  C                       Primary basis for the recommendations was expert's consensus.
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Abbreviations:** RCTs, randomized controlled trials; VTE, venous thromboembolism.

###### 

Classifi cation of recommendations

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Strength of recommendations   Recommendations based on evidence and expert opinion
  ----------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Class I                       Conditions for which there is evidence for and/or agreement of opinion that the procedure (or treatment) is useful/effective.

  Class II                      Conditions for which there is little evidence for and/or divergence of opinion that the procedure (or treatment) is useful/effective.\
                                a The weight of evidence or opinion favors the procedure (or treatment).\
                                b Usefulness/efficacy is less established by evidence or opinion.

  Class III                     Conditions for which there is evidence for and/or agreement of opinion that the procedure (or treatment) is NOT useful/effective and in some cases may be harmful.
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Results
=======

Risk factors
------------

Each risk factor was evaluated separately as much as possible. The risk factors for VTE in clinical patients, according to the level of evidence, are listed in [Table 3](#tbl3){ref-type="table"}. [Table 4](#tbl4){ref-type="table"} shows the frequency of VTE in hospitalized patients with various medical conditions.

###### 

Risk factors for VTE in medical patients according to the level of evidence

  A                             B
  ----------------------------- --------------------------------------
  Age ≥ 55 years                Active rheumatologic diseases
  AMI                           Inflammatory bowel diseases
  Cancer                        Infections
  Chemotherapy                  Obesity
  CHF class III or IV           Peripheral arterial insufficiency
  CVC and PAC                   Reduced mobility
  HCVA                          Varices/chronic venous insufficiency
  Hormonotherapy                
  HRT and HC                    
  ICU admission                 
  ICVA                          
  Nephrotic syndrome            
  Paresis/paralysis of legs     
  Pregnancy and puerperium      
  Previous VTE                  
  Severe respiratory diseases   
  Thrombophilias                

**Abbreviations:** AMI, acute myocardial infarction; CHF, congestive heart failure; CVC, central venous catheters for general use and hemodialysis catheters; HC, hormonal contraceptives; HCVA, hemorrhagic cerebral vascular accident; HRT, hormonal replacement therapy; ICU, intensive care unit; ICVA, ischemic cerebral vascular accident; PAC, pulmonary artery catheters; VTE, venous thromboembolism.

###### 

Frequency of DVT in hospitalized patients according to their medical condition

  Condition                       DVT (%)
  ------------------------------- ---------
  CVA                             28--75
  CHF class III or IV             15--71
  AMI                             10--63
  Nephrotic syndrome              14--43
  ICU admission                   25--31
  Active rheumatologic diseases   10--30
  Severe respiratory diseases     9--29
  Infection                       7--16

**Abbreviations:** AMI, acute myocardial infarction; CVA, cerebral vascular accident; CHF, congestive heart failure; DVT, deep venous thrombosis; ICU, intensive care unit.

**Note:** Frequency based on studies using screening for DVT in patients without prophylaxis.

### Active rheumatologic diseases and inflammatory bowel disease\\

Although rheumatologic diseases represent a heterogeneous group of patients, they have usually been considered at-risk for thrombosis because incidences of VTE of 10% to 30% have been demonstrated in hospitalized patients with active rheumatologic diseases ([@b33]; [@b4]; [@b175]). [@b31] in an analysis of 540 patients with suspected DVT, detected systemic lupus erythematosus (SLE) as a risk factor for VTE (OR 4.3; 95% CI 3.1--5.5). However, Orger and colleagues (1997) in a very similar study with 277 patients, found different results (OR 0.7; p = NS), that were confirmed in a case-control study with 1,272 SLE patients (OR 1.6; p = NS) ([@b186]). In the secondary analyses of the MEDENOX study about the importance of risk factors, the association of VTE with rheumatologic diseases was not statistically significant (RR 1.6; 95% CI 0.96--2.69, p = 0.11). Based on these data, active rheumatologic diseases as a group, and SLE in particular, are not clearly related to increased VTE risk. However, lupus anticoagulant (LA) and anticardiolipin (ACL) antibodies are frequently found in rheumatologic patients and are definitely related to thrombotic phenomena. [@b52], studying 173 SLE patients, found that LA was associated with VTE with an OR of 6.4 (95% CI 2.7--15.4).

Arterial and venous thromboses are common clinical findings in patients with Behcet' disease (BD) ([@b109]). ACL has been found in as many as 30% of these patients ([@b223]), but other studies demonstrate vascular thrombosis even when an ACL antibody is not found ([@b105]; [@b129]). A HLA-B51 positive is associated with a higher risk of VTE (OR 4.2; 95% CI 1.1--16.3) and a HLA-B35 has a protective effect (OR 0.2; 95% CI 0.04--0.92) ([@b99]).

IBD was evaluated by [@b16] in a retrospective cohort including 2,857 patients with Crohn's disease (CD) and 2,672 with ulcerative colitis (UC). Compared with controls both CD and UC patients had increased risk for DVT (RR 4.7; 95% CI 3.5--6.3 in CD and RR 2.8; 95% CI 2.1--3.7 in UC) and for PE (RR 2.9; 95% CI 1.8--4.7 in CD and RR 3.6; 95% CI 2.5--5.2 in UC) ([@b99]). [@b144] studied 618 patients with IBD, 243 patients with rheumatoid arthritis and equal number of gender and aged-matched control. The authors found that IBD was significantly associated with a higher chance of developing VTE (OR 3.6; 95% CI 1.7--7.8; p \< 0.001), but that rheumatoid arthritis was not (OR 0.7; 95% CI 0.2--2.9; p = NS).

In summary, IBD, BD, and positive LA and ACL antibodies in SLE patients should be considered as risk factors for VTE (EVIDENCE A). Active rheumatologic diseases as a group receive a level of evidence B, while SLE without LA or ACL and rheumatoid arthritis should not be considered as risk factors for VTE.

### Acute myocardial infarction

The risk for VTE in acute coronary syndromes' patients is high, but the specific evaluation of VTE risk in this setting has become difficult because the use of heparin and other medications that interfere directly with the coagulation system is now routine. Most data about VTE risk in acute coronary syndromes come from old studies, with small number of patients, comparing placebo with some kind of prophylaxis. One study showed an incidence of DVT as high as 62.5%, when the treatment for AMI was basically absolute bedrest for 5 days ([@b222]). In a study comparing LDUH with placebo, PE was detected in 12.2% (5/41) in the placebo group, compared with 0/37 in the heparin group ([@b48]). AMI should therefore, be considered a risk factor for VTE (EVIDENCE A).

### Admission to ICU

Several studies that employed screening for DVT in critically ill patients showed that admission to an ICU is a risk factor for VTE (RR 1.8 to 2.9) ([@b27]; [@b87]; [@b80]; [@b61]; [@b132]; [@b96]; [@b56]; [@b62]). The incidence of DVT in clinical ICUs is very high, particularly in patients receiving no prophylaxis (25% to 31%), compared with those that receive some form of prophylaxis (11 to 16%) (EVIDENCE A) ([@b27]; [@b96]; [@b56]; [@b62]). Besides, PE is found in up to 27% of ICU patients that undergo autopsy. Although PE contributes to death in about 12% of ICU patients, it is suspected before death in only 30% of the cases. ICU patients have in general 2 to 4 additional risk factors for VTE, not including reduced mobility ([@b185]; [@b60]). Nevertheless, according to several reports, the utilization of prophylaxis in ICU patients had been quite irregular ([@b89]; [@b119]; [@b185]; [@b180]; [@b60]; [@b114]; [@b180]).

### Age

Several epidemiologic studies have shown that the incidence of VTE increases exponentially with aging. It is not clear if the reasons for this are changes in clotting mechanisms or the presence of thrombogenic comorbidities ([@b5]; [@b197]). In a study conducted in Oslo, the incidence of VTE increased from 1:10,000 at age 20 to 1:1,000 at age 50 ([@b202]). Other studies showed different age cutoffs for significant increase in risk of VTE: RR 1.75 for age \>65 years, 1.51 for age \>75 years and 2.0 for age \>85 years ([@b108]; [@b3]; [@b157]). In the study EPI-GETBO, the authors screened 234 medical patients on the day of admission with Doppler ultrasound, and found that the prevalence of asymptomatic DVT, among patients older than 80 years, reached 17.8% (95% CI 8.5--32.6) and the incidence 6.0 per 1,000 patients-day (95% CI, 0--12.7) ([@b158]). In the study performed in the community of Worcester, MA, the risk of VTE almost doubled at each decade from the 5th decade on (RR 1.9) and the incidence of VTE was 62:100,000, starting at age 50 ([@b5]). For the same age, others studies showed an incidence of VTE reaching 100:100,000 ([@b197]; [@b72]). Therefore, we conclude that there is a progressive increase in VTE risk with advancing age, and that age over the 5th decade should be considered as an additional risk factor for VTE in medical patients (EVIDENCE A).

### Cancer, chemotherapy, and hormonotherapy

Association between cancer and thromboembolism is known since 1865, when Trousseau described migratory thrombophlebitis as a sign for underlying pancreatic cancer (EVIDENCE A). Since then, many others neoplasias have been associated with VTE ([Table 5](#tbl5){ref-type="table"}) ([@b166]; [@b205]). This high incidence of VTE may be explained not only by the hypercoagulability but also by the action of some antineoplastic agents and the frequent venous catheterization. In some studies the higher incidences of DVT were observed in patients with pancreas, ovarium, liver, and brain cancer, while others indicate breast, lung, genital, urinary, stomach and colon cancers as the most frequently related to VTE ([@b35]; [@b26]; [@b200]). In a series of 21.530 autopsies, 29% of the patients had cancer and the most common were ovarium, extrahepatic biliary tree, and stomach (34.6%, 31.7%, and 15.2%, respectively), while esophagus, larynges, leukemia, and lymphoma had the lower prevalences ([@b35]; [@b26]; [@b200]).

###### 

Relative risk for VTE in different neoplasias

  Origin          Patients with VTE   Total of patients   RR (95% CI)
  --------------- ------------------- ------------------- --------------------
  Head and neck   35                  20,924              0.29 (0.2--0.4)
  Bladder         180                 74,517              0.42 (0.36--049)
  Breast          469                 186,273             0.44 (0.4--0.48)
  Esophagus       64                  147,42              0.76 (058--0.97)
  Cervix          53                  102,36              0.90 (0.68--1.18)
  Liver           121                 229,38              0.92 (0.76--1.110)
  Prostate        1230                218,743             0.98 (0.93--1.04)
  No cancer       46.848              8,177,634           1.0
  Rectum          417                 65,837              1.11 (1.0--1.22)
  Lung            1.504               232,764             1.13 (1.07--119)
  Colon           1.320               168,832             1.36 (1.29--1.44)
  Renal           278                 34,376              1.41 (1.25--1.59)
  Stomach         280                 32,655              1.49 (1.33--1.68)
  Lymphoma        537                 52,042              1.80 (1.65--1.96)
  Pancreas        488                 41,551              2.05 (1.87--2.24)
  Ovarium         327                 26,406              2.16 (1.93--2.41)
  Leukemia        591                 47,234              2.18 (2.01--2.37)
  Brain           184                 13,529              2.37 (2.04--274)
  Uterus          226                 11,606              3.34 (2.97--3.87)

Chemotherapy and hormonotherapy may also be thrombogenic (EVIDENCE A). However, it's difficult to separate the effect of the treatment from the effect of the cancer itself. Several studies have shown that VTE is more common during chemotherapy in breast cancer patients, compared with the period without treatment (6.8% vs 17.6%) ([@b68]; [@b120]; [@b191]; [@b173]). [@b191] observed a higher incidence of VTE when tamoxifen was used. In a study with mieloma patients, [@b220] observed that addition of thalidomide to chemotherapy was associated with an important increase in DVT incidence (28% vs 4%, p = 0.002).

### Central venous catheters

Several variables are implicated in the increased thrombogenicity associated with central venous catheters (CVC-thrombosis) and DVT in patients using catheters ([Table 6](#tbl6){ref-type="table"}). Given the high variability of catheter-related factors and underlying diseases, studies evaluating CVC-thrombosis are quite heterogeneous. Besides, the diagnostic methods for thrombosis and the primary objectives of these studies are extremely variable, which make it difficult to group then in order to make specific recommendations. For these reasons, we discuss thrombosis prophylaxis according to the purpose of the catheter: for chemotherapy in cancer patients, for parenteral nutrition (PN) and for general use in ICU patients. We briefly discuss also the evidence for pulmonary artery catheters and hemodialysis catheters as risk factors for thrombosis.

###### 

Factors associated with venous thrombosis in patients with catheters

  Variables                                                                                                    Relative risk
  ------------------------------------------------------------------------------------------------------------ -------------------------
  Catheterization of femoral vein[1](#tf6-1){ref-type="table-fn"}                                              4.7--6.0 (OR 7.7--23.5)
  Catheterization of axilary, subclavian or internal jugular veins[2](#tf6-2){ref-type="table-fn"}             3.9--11.6
  Catheterization of femoral vein vs. subclavian or internal jugular veins[3](#tf6-3){ref-type="table-fn"}     4.7--7.4
  Catheterization of internal jugular vein vs. subclavian vein[4](#tf6-4){ref-type="table-fn"}                 4.1
  Catheterization of left subclavian vein vs. right subclavain vein[5](#tf6-5){ref-type="table-fn"}            1.2
  Infusion of parenteral nutrition vs.                                                                         2.6
  other solutions[6](#tf6-6){ref-type="table-fn"}                                                              
  Catheter material (polyvinyl or polyethylene vs. polyurethane or silicone)[7](#tf6-7){ref-type="table-fn"}   3.6--6.0
  Catheter duration[8](#tf6-8){ref-type="table-fn"}                                                            1.04
  Number of attempts to insertion (one vs. two)[9](#tf6-9){ref-type="table-fn"}                                11.8
  Long-term central catheters vs. long-term peripherakl catheters[10](#tf6-10){ref-type="table-fn"}            2.2
  Catheters in patients with anti-thrombin III deficiency[11](#tf6-11){ref-type="table-fn"}                    OR 8.4
  Catheters in patients with factor V Leiden[12](#tf6-12){ref-type="table-fn"}                                 2.3

**Notes:**([@b209]; [@b45]; [@b141]; [@b93])

([@b102]; [@b133])

([@b209]; [@b140])

([@b39]; [@b206])

([@b69]; [@b39])

([@b110])

([@b22]; [@b150])

([@b23]; [@b88])

([@b110])

([@b113])

([@b128]; [@b39])

([@b212])

Several studies show that the incidence of thrombosis is higher in the catheterized veins than in contralateral veins ([@b174]; [@b45]; [@b141]; [@b133]; [@b93]). Besides, in RCTs of prophylaxis, the incidence of CVC-thrombosis is 5%--18% in the groups that receive prophylaxis and 4%--62% in the groups that do not receive prophylaxis. Therefore, central venous catheters constitute additional risk factors for VTE in clinical patients ([@b77]) in general and in oncologic patients ([@b17]; [@b8]; [@b39]) in particular (EVIDENCE A).

#### Pulmonary artery catheters (Swan-Ganz)

The rate of clot formation in pulmonary artery catheters is time dependent and ranges from 66% to almost 100% in noncoated catheters with heparin ([@b81]; [@b29]; [@b131]; [@b149]). Nevertheless, the frequency of thrombotic complications reported varies considerably, depending on the method of detection of the thrombus ([@b47]). Similarly to other CVC, pulmonary artery catheters lead to a 4.5 higher relative risk of thrombosis of the catheterized vein as compared with the contralateral veins ([@b139]), and constitute an additional risk factor for VTE ([@b180]) (EVIDENCE A).

#### Hemodialysis catheters

Although moderate to severe renal insufficiency is associated with higher risk of bleeding ([@b127]), thromboembolic events are also quite common in patients with renal failure. Chronic hemodialysis patients present high incidence of thrombophilias, frequently utilize recombinant erithropoetin, which may have a prothrombotic effect and present also VTE risk factors that are less commonly recognized, such as hyperhomocysteinemia, endothelial dysfunction and markers of systemic inflammation ([@b28]). In a study of the US Renal Data System with 76,718 renal failure patients on chronic dialysis in 1996, the incidence of PE was 149.9/100,000, while the incidence of PE in the general US population was 24.6/100,000 ([@b210]). Furthermore, thrombosis of the venous access is another well established condition in these patients, affecting arterial-venous fistulas, grafts and double-lumen catheters for hemodialysis ([@b51]). These catheters are most commonly used as temporary vascular accesses but in some instances, allow hemodialysis for longer periods ([@b196]). Catheter malfunction is quite common and the incidence of CVC-thrombosis in these patients is up to 46% ([@b51]; [@b10]), however, the need for catheter removal is rare. Also, the cannulation of subclavian veins lead more frequently to thrombosis and/or stenosis than the cannulation of internal jugular veins ([@b214]; [@b10]; [@b2]), particularly on the left side ([@b30]). Thus, there is evidence that hemodialysis catheters, similarly to other CVC constitute an additional risk factor for VTE (EVIDENCE A).

### Cerebral vascular accident

Hospitalized patients with CVA present one of the highest rates of VTE among general medical patients, ranging from 28% to 75% and affecting particularly the paralyzed limb ([@b137]). In a retrospective cohort were analyzed 1,953 patients with hemorrhagic CVA and 15,599 patients with ischemic CVA ([@b71]). The authors found a prevalence of VTE four-fold higher for patients with hemorrhagic CVA and even after controlling for severity of disease and duration of hospitalization, hemorrhagic CVA was an independent risk factor for VTE with an OR of 2.6 (95% CI 1.5--4.6). In another study, PE was found to be the immediate cause of death in 5% of stroke patients ([@b163]). For these reasons both ischemic and hemorrhagic CVA must be considered important risk factors for VTE (EVIDENCE A).

### Congestive heart failure

Many studies have shown that CHF is related to VTE, especially in patients with reduced mobility. In a case-control study with 790 patients, CHF increased significantly the risk for VTE (OR 2.6; 95% CI 1.4--4.7) ([@b84]). Besides, the lower the ejection fraction the higher the risk of VTE: OR 38.3 for EF \<20%; 2.8 for EF from 20% to 40%, and 1.7 for EF \>45%. In a cohort study with 1,250 patients, [@b77] detected CHF as an independent risk factor for VTE in patients presenting with fatal PE at autopsy (OR 2.8; 95% CI 1.8--4.2). Samama, in another case-control study, also identified CHF as a risk factor for VTE in ambulatorial patients (OR 2.9; 95% CI 1.5--5.6) ([@b186]). Even in patients treated with anticoagulants due to a previous VTE episode, CHF was considered an independent risk factor for new VTE episodes (OR 2.3; 95% CI 1.1--5.0) ([@b43]). Although an analysis of the MEDENOX study failed to consider CHF as an independent risk factor for VTE, the risk associated with CHF was observed to be higher among patients with more severe functional compromise (RR 0.87; 95% CI 0.6--1.3 for New York Heart Association \[NYHA\] class III and RR 1.3; 95% CI 0.74--2.34 for NYHA class IV). CHF must be considered an important risk factor for VTE, particularly among patients with NYHA classes III and IV (EVIDENCE A).

### Hormonal contraception and hormonal replacement therapy

HRT and HC increase the risk for VTE by 2 to 6 times (EVIDENCE A). Recently, two well designed RCTs confirmed the association between VTE and HRT ([@b85]; [@b183]). In the HERS Study (Heart and Estrogen/progestin Replacement Study), 2,763 women with coronary disease were followed prospectively and an increase in the risk for VTE was noted among those women treated with estrogen and progesterone (RR 2.7; 95% CI 1.4--5.0 for VTE and RR 2.8; 95% CI 0.9--8.7 for PE). A few years later, in the Women's Health Initiative (WHI), the group receiving HRT had a RR of 2.1 (CI 95% 1.6--2.8) for the development of VTE when compared to the placebo group. The risk is higher in the first year of HRT use ([@b164]; [@b82]; [@b145]), especially in the presence of previous history of VTE ([@b82]). [@b194] showed that the risk of VTE was higher with oral, compared with transdermic, administration of HRT (RR 4.0; 95% CI 1.9--8.3).

Several observational studies and some RCTs have documented a RR 3 to 6 times higher in HC users, compared with nonusers (EVIDENCE A) ([@b91]; [@b121]; [@b43]; [@b213]). In a multicentric, international case-control study including 1,143 cases of VTE and 2.998 controls, HC was associated with an OR of 4.1 (95% CI 3.1--5.6) in European women and to an OR of 3.2 (95% CI 2.6--4.1) in women from developing countries (WHO 1995). As for HRT, the risk is higher during the first year of use ([@b203]; [@b122]), and it seems also higher for the 3rd generation hormones (desogestrel and gestoden) ([@b100]).

### Infections

Several cohorts and prospective randomized trials have indicated the association between infections and VTE. However, most patients included in these studies have lung infections and are described in the specific section about respiratory diseases. The SIRIUS study ([@b186]) included 1,272 ambulatory patients and demonstrated that infection is a risk factor for VTE (OR 1.95; 95% CI 1.31--2.92). However, in this study the site of the infections are not reported. [@b104] studied 101 acutely ill patients with labeled fibrinogen and found that those with pneumonia or cardiac diseases had an incidence of DVT of 20% while the patients with other diagnoses had an incidence of DVT of only 4%. In this study, 4 of the 22 patients with pneumonia had DVT, while none of the patients with urinary tract infection, bronchitis, acute enterocolitis or sepsis developed DVT. In the prospective registry 'DVT FREE', [@b66] evaluated 5,451 patients with acute DVT confirmed by Doppler ultrasound, demonstrating that 22% of the patients had an infection as one of the comorbidities (pneumonia in 7%, sepsis in 5%, and other infections in 10%). They also showed that thoracic infections were more common among those with PE and DVT, than among those with DVT alone (10% vs 8% p = 0.04). [@b3] analyzed the data of 866 patients of the MEDENOX study, demonstrating that the acute infections were one of the main risk factors for VTE in the univariate (RR 1.47; 95% CI 1.47--2.14) and multivariate analyses (OR 1.74; 95% 1.12--2.75). These data suggest that infections are an additional and frequent risk factor for VTE, especially in hospitalized patients (EVIDENCE A for pulmonary infection and B for the other infections).

### Nephrotic syndrome

The association between nephrotic syndrome (NS) and thromboembolic events is recognized since 1837 ([@b208]). Until the 70s, some authors suggested that renal vein thrombosis was possibly the cause of the NS ([@b101]; [@b14]). Nevertheless, several studies confirmed that the thrombotic episodes are a consequence of the factors leading to the hypercoagulability found on the NS ([@b125], [@b127]; [@b156]; [@b124]; [@b12]) The global incidence of thrombosis in NS is 43% ([@b12]), but PE and DVT affect about 11% of the patients ([@b155]). The frequency of renal vein thrombosis in the membranous NS, in adults, varies among studies from 5% to 60% ([@b161]; [@b155]). These episodes are symptomatic in only 10% of the cases ([@b161]), and all episodes can be accurately detected by computed tomography ([@b59]). [@b184] reviewed 13 prospective studies, including 682 patients with NS, showing that the incidence of renal vein thrombosis was 21.4% (95% CI 18%--25%). These authors reviewed also three other studies with 148 patients and found that incidence of PE was 14% (95% CI 9%--21%). Thromboembolic phenomena, particularly renal vein thrombosis, are more common with membranous lesions ([@b216]; [@b124]; [@b155]), and possibly when serum albumin is \<2g/dL ([@b98]; [@b112]; [@b179]; [@b155]). For hospitalized patients with reduced mobility, NS is a risk factor for VTE (EVIDENCE A).

### Obesity

There are many studies that evaluate obesity direct or indirectly as a risk factor for VTE leading to some debate about the importance of it as a risk factor. [@b3], analyzing the data of the MEDENOX study, did not find a significant correlation between obesity and VTE (RR 1.04; 95% CI 0.69--1.60). [@b70], evaluating women with body mass index (BMI) above 27, also failed to find such a correlation. It is important to mention that in both studies the identification of obesity as a risk factor was a secondary objective and the analysis was done post hoc. Besides, the definition of obesity currently accepted as the BMI ≥30 Kg/m^2^, is not used in all studies. For example, in a study of consecutive out-patients with clinical suspicion of VTE, [@b31] defined obesity as 30% excess above ideal body weight and did not find that obesity was a risk factor for VTE. [@b77], in a population based case-control study reached the same conclusion.

On the other hand, several studies do implicate obesity as a risk factor for VTE. [@b18] found in an autopsy study (n = 7,227) a higher incidence of VTE in obese (67%) than in nonobese (14%), RR 2.97 (95% CI 1.78--4.93). Four prospective cohort studies support theses findings, with RR ranging from 2.0 to 3.92 ([@b31]; [@b63], [@b65]; [@b72]). Although there is some debate, the evidence from prospective trials evaluating risk factors support the correlation between obesity and VTE. Nevertheless, the RR for obesity is relatively low (between 2 and 3) but increases significantly when there are additional risk factors for VTE. Indeed, the RR rises from 2 to 10 with the use of HC in obese patients ([@b1]). In summary, we conclude that obesity is an important coadjuvant for the development of VTE (EVIDENCE B).

### Paresis/paralysis of the lower extremities

There is supporting evidence that paresis or paralysis of the lower extremities is associated with VTE, even when not secondary to CVA (EVIDENCE A). In a study with 143 patients that developed acute hemiplegia, the incidence of VTE was 26% and the risk was higher during the first 4 weeks ([@b178]). [@b169] studied the presence of risk factors among 450 hospitalized medical patients and found that paralysis was associated with an increased chance of VTE (calculated OR 12.5; 95% CI 1.5--104.5). The same result was seem in a case-control study with 620 patients older than 65 years (OR 2.1; 95% CI 1.0--4.1) ([@b217]). Patients with paresis or paralysis of the legs must be considered as at-risk for VTE, particularly during the acute setting (EVIDENCE A).

### Peripheral vascular diseases

The impact of varices of the lower extremities as an additional risk factor for VTE in medical patients is controversial. There are few studies evaluating the theme and there is no evidence that surgical treatment of the varicose veins decreases the potential risk of VTE. [@b94] showed that the incidence of VTE by labeled fibrinogen in surgical patients with mild to severe varices was 56.5%, leading to a RR of 2.3. The reason for such a high incidence of VTE in patients with varices is not known but one of the possibilities is that the varices may be a consequence of previous and undiagnosed DVT. Recently, [@b77] demonstrated in a population-based, case-control study that varices are associated with risk of VTE in medical patients, but the risk decreases with age: OR 4.2 at age 45, 1.9 at age 60 and 0.9 at age 75. In another analysis of the same data ([@b76]), the attributable risk of VTE to varices was 6%; but after adjustments for other confounders, such as hospitalization, trauma, cancer and chemotherapy, CHF and CVA, CVC or pacemaker, the risk associated with varices became zero. Some cohort studies also failed to demonstrate an independent association between varices and VTE ([@b62]; [@b104]). On the other hand, prospective studies with good methodology ([@b4]; [@b160]) and case control studies ([@b186]; [@b169]) showed that varices (OR ≥ 2.5 and RR 4.2) and venous insufficiency (OR ≥ 1.7) were significantly associated with VTE in medical patients. Furthermore, one case-control study in ambulatory patients with clinical suspicion of DVT or PE showed that peripheral arteriopathy was related to an higher chance of VTE (OR 1.9) ([@b31]). Therefore, peripheral venous and arterial diseases may be considered as cofactors for the development of thrombosis (EVIDENCE B).

### Pregnancy and puerperium

Pregnancy is a well known condition related to increased risk of thrombosis ([@b186]), that persists even a few months after delivery (EVIDENCE A). It is estimated that the risk for VTE during pregnancy increases 3 to 4 times, probably because of the increase in procoagulant factors, such as factor VIII and in the resistance to activated protein C. [@b188], in a population-based study with more than 24,000 women, reported an incidence of VTE during pregnancy and postpartum of 103:100,000 (95% CI 55--177). Besides, fatal PE remains one of the most important complications during pregnancy and puerperium, especially in those women older than 40 years ([@b57]).

### Previous VTE

Previous VTE has been consistently described as a risk factor for the development of VTE in several scenarios: hospitalized and ambulatorial patients and in the general population (EVIDENCE A). The case-control study SIRIUS ([@b186]) revealed a strong tendency to new thrombotic events in ambulatorial patients with previous history of VTE (OR 15.6). In a prospective study, [@b160] showed that medical patients with suspected DVT and history of VTE had increased chance of confirming the diagnosis by venography (OR 1.7). In 2003, Tosseto and colleagues (2003) also demonstrated increased risk of VTE in individuals with previous history of this condition (OR 6.8). A case-control study showed that previous history was an important risk factor for VTE also in hospitalized medical patients (OR 4.7) ([@b21]). Another case-control study showed that in hospitalized medical patients older than 64 years-old, previous VTE was independently associated with the development of VTE during hospitalization (OR 3.4) ([@b217]). In the analysis of VTE risk factors based on the MEDENOX study ([@b3]), previous history was associated with the development of VTE, in univariate (RR 1.8; p = 0.02) and multivariate logistic regression (RR 2.1; p = 0.02). Thus, previous history of thrombosis should be considered as an additional risk factor for VTE in medical patients (EVIDENCE A).

### Reduced mobility

It is not known exactly what level and duration of immobility is associated with increased risk of VTE. What is recognized is that when important risk factors are present, even subtle reductions in mobility increase the overall risk of VTE. It is believed that when patients are able to ambulate to the bathroom or on the hallways, but have to come back, for any reason (eg, need for intravenous infusions or oxygen therapy, generalized weakness, pain, or dyspnea on exertion), and stay in bed or chair while hospitalized with an acute illness, they are at-risk for VTE.

Some studies tried to identify the loss of mobility as the main factor leading to VTE. [@b153] evaluated 1,000 patients with Doppler ultrasound for suspected DVT and noted that there was a significant correlation between loss of mobility for more than 3 days and development of DVT. In a large case-control study with 1,272 ambulatory patients, [@b186] showed that standing for more than 6 hours and resting in bed or chair were associated with an increased odds of VTE (OR 1.9; 95% CI 1.1--3.1 and OR 5.6; 95% CI 2.3--13.7, respectively). Similarly, [@b77] showed that hospitalization or admission to a long-term care facility increased the risk of VTE (OR 8.0; 95% CI 4.5--14.2). Other studies identify the reduction of mobility as a risk factor for VTE, but the definition of decreased mobility is either not clearly stated or it is quite variable, including complete bed rest for ≥ 5 days ([@b5]), partial or complete bedrest for at least 10 days ([@b73]), reduced mobility for more than half of the day, at least during 7 days ([@b115]). Other authors noted that more serious loss of mobility, such as the incapacity to walk independently for more than 10 meters were frequently associated with the development of VTE ([@b4]). In a recent case-control study of hospitalized patients older than 65 years, reduced mobility was an independent risk factor for VTE (OR 1.73 to 5.64), depending on the degree of immobility ([Table 7](#tbl7){ref-type="table"}) ([@b217]). The risk was higher in patients with more severe limitation of mobility (bedrest vs wheel-chair) and when the loss of mobility was recent (\<15 days vs ≥30 days).

Based on presented data, we believe that the patient who stays in bed or chair for more than half of the day (excluding sleep time) must be considered as having reduced mobility and is at-risk for VTE (EVIDENCE B). The immobility that is more recent and severe is more strongly associated with the development of VTE.

### Respiratory diseases

Respiratory diseases such as COPD and pneumonia are frequently cited as VTE risk factors, but studies evaluating specifically the impact of these conditions in the incidence of VTE are rare. Besides, the diagnosis of VTE in COPD patients is usually a challenge because PE may present simply as worsening of dyspnea in a patient with chronic respiratory failure. On the study performed in the community of Worcester, MA, the diagnosis of COPD was present in 18% of those with DVT and in 34% of patients with PE ([@b5]). In autopsy studies, DVT has been diagnosed in 18% to 51% of COPD patients, giving an OR of 1.6 for emphysema as compared with controls with median age \>81 years-old ([@b148]; [@b90]). In prospective cohorts of patients with exacerbation of COPD, DVT was detected in 9% of patients by venography and/or labeled fibrinogen ([@b171]), in 11% by Doppler ultrasound ([@b195]; [@b49]), and in 29%, when combining ventilation-perfusion scanning and Doppler ultrasound ([@b147]). Patients treated for VTE with oral anticoagulation in a RCT were analyzed, and the authors demonstrated that chronic respiratory diseases increased the risk for recurrence of VTE (OR 1.91; 95% CI 0.85--4.26) ([@b43]). On the other hand, the analyses of patients with risk factors for VTE in the MEDENOX study surprisingly revealed that chronic respiratory disease was not significantly associated with an increased risk (OR 0.6; 95% CI 0.38--0.92)([@b3]). However, it is worthy noticing that these analyses were performed post hoc and based on secondary objectives of the MEDENOX study.

Prospective controlled studies evaluating the efficacy of VTE prophylaxis are helpful in identifying pulmonary conditions as risk factors for VTE because the rates of thrombosis can be compared between patients on control and treatment groups. [@b11], in a small study with patients with thoracic infection or CHF, showed a significant difference in the incidence of DVT diagnosed by labeled fibrinogen, favoring LDUH (5,000 IU 8--8h) versus placebo (4% vs 26%, respectively, p \< 0.01). In another RCT, patients with exacerbation of COPD, requiring ventilatory support (the majority with thoracic infection), were randomized to LMWH (nadroparin 3,800 IU AXa or 5,700 IU AXa) or placebo ([@b56]). Those receiving LMWH had significantly lower incidence of VTE, when compared with placebo (28.2% vs 15.5% respectively, p = 0.045). In the study THE-PRINCE ([@b106]), patients with severe respiratory diseases (SRD) or CHF were randomized to enoxaparin 40 mg/daily or LDUH 5,000 IU three times daily. The authors demonstrated that the incidence of VTE by venography was high in all patients, without significant differences among all patients receiving enoxaparin and LDUH (8.4% vs 10.4%), or among patients with SRD (7.1% vs 5.9%). The definition of SRD in this study was the presence of abnormalities in the pulmonary function tests, arterial blood gas analyses or both, and at least one of the following conditions: acute exacerbation of COPD, severe secondary pulmonary hypertension, pneumonia, interstitial lung disease, lung cancer and/or metastasis and life expectancy of less than 2 months. This description is broad enough to include the main pulmonary diagnoses that are associated with an increase risk of VTE in hospitalized medical patients, and was therefore, incorporated to our algorithm instead of each pulmonary disease separately. In summary, there is some controversy about the role of specific respiratory diseases as risk factors for VTE in hospitalized medical patients. However, in general, patients presenting diagnostic criteria for SRD have increased risk for VTE (EVIDENCE A).

###### 

Reduced mobility as a risk factor for VTE

  Degree of immobility      OR     95% CI        P
  ------------------------- ------ ------------- --------
  Normal                    1.0    \-            \-
  Limited                   1.73   1.08--2.75    0.02
  Wheel-chair ≥ 30 days     2.43   1.37--4.30    0.002
  Bedrest ≥ 30 days         2.73   1.20--6.20    0.02
  Wheel-chair 15--30 days   3.33   1.26--8.84    0.02
  Bedrest 15--30 days       3.37   1.00--11.29   0.05
  Wheel-chair \<15 days     4.32   1.50--12.45   0.007
  Bedrest \<15 days         5.64   2.04--15.56   0.0008

### Thrombophilias

Hereditary thrombophilias, particularly antithrombin III (ATIII), protein C (PC) and protein S (PS) deficiencies, and factor V Leiden (FVL) are well known risk factors for VTE. Several case-control studies and some prospective registries show level A evidence for these thrombophilias as risk factors for thrombosis ([Table 8](#tbl8){ref-type="table"}). In a recent prospective registry of thrombophilic families, the incidence of VTE was 16% among relatives with thrombophilia, against 1% among those without thrombophilia (RR 15.7; 95% CI 9.6--28.0) ([@b215]). In a multicenter study with 233 Italian families, [@b25] showed that ATIII deficiency is associated with a higher risk for VTE than other genetic conditions (RR 4.4 for ATIII vs FVL, 2.6 for ATIII vs PS, and 1.9 for ATIII vs PC). [@b198] reported that conditions such as surgery, trauma, immobilization, pregnancy, puerperium, and hormonal contraception increase the risk for thrombosis in patients with ATIII, PS or PC deficiencies. Mutation of the prothrombin gene has also been associated with increased risk for VTE in different populations (OR 2.0 to 11.5) ([@b168]; [@b24]; [@b38]; [@b78]; [@b97]; [@b118]; [@b201]; [@b7]). It is appropriate to conclude that hereditary thrombophilias confer additional risk for VTE in hospitalized patients (EVIDENCE A).

###### 

Annual incidence and VTE risk in hereditary thrombophilias

  Author, year   Patients/controls                              Design         ATIII         PC            PS                                            FVL                                      MPG       Combination
  -------------- ---------------------------------------------- -------------- ------------- ------------- --------------------------------------------- ---------------------------------------- --------- ----------------
  [@b53]         28/53[†](#tf8-1){ref-type="table-fn"}          PC/8 years     12.0%         2.80%         3.30%                                         \-                                       \-        \-
  [@b162]        44/49                                          PC             \-            2.50%         3.50%                                         \-                                       \-        \-
  [@b111]        474/474                                        CC             OR 2.2--5.0   OR 3.1--6.5   OR 0.7--1.6[§](#tf8-3){ref-type="table-fn"}   \-                                       \-        \-
  [@b168]        442/463                                        CC             \-            \-            \-                                            \-                                       OR 2.8    \-
  [@b97]         50/50                                          CC             \-            \-            \-                                            \-                                       OR 11.5   \-
  [@b78]         99/282                                         CC             \-            \-            \-                                            \-                                       OR 3.8    \-
  [@b38]         219/164                                        CC             \-            \-            \-                                            \-                                       OR 5.4    \-
  [@b24]         504                                            RC             \-            \-            \-                                            OR 5.8                                   OR 2.0    \-
  [@b50]         327/317                                        CC             \-            \-            OR 2.4                                        \-                                       \-        \-
  [@b118]        366/400                                        CC             \-            \-            \-                                            x                                        OR 3.7    OR 4.8
  [@b201]        116/201                                        CC             \-            \-            \-                                            \-                                       OR 3.1    \-
  [@b142]        437                                            RC             \-            \-            \-                                            0.45%. RR 4.2                            \-        \-
  [@b134]        150/723                                        RC             RR 8.1        RR 7.3        RR 8.5                                        RR 2.2                                   \-        \-
  [@b135]        583                                            RC             OR 21.2       OR 12.6       OR 19.9                                       \-                                       \-        OR 9.0
  [@b190]        94/208[†](#tf8-1){ref-type="table-fn"}         PC/3 years     1.60%         1.00%         0.40%                                         \-                                       \-        \-
  [@b25]         233/513                                        RC             1.07%         0.54%         0.50%                                         0.30%                                              
  [@b198]        793                                            RC             x             x             x                                             0.11%. RR 2.5                                      0.40%. RR 10.6
  [@b182]        15109                                          TC             \-            OR 1.7        \-                                            RR 3.3                                   \-        \-
  [@b211]        48/44                                          CC             1.10%         \-            \-                                            x                                        x         4.60%
  [@b7]          229/246                                        CC             \-            \-            \-                                            OR 6.9                                   OR 2.4    \-
  [@b117]        233                                            RC             \-            \-            \-                                            0.56%                                    \-        \-
  [@b143]        247/470[†](#tf8-1){ref-type="table-fn"}        PC/3.3 years   \-            \-            \-                                            0.58%                                    \-        \-
  [@b54]^a^      14358                                          PC/8.1 years                 RR 3.36                                                                                                        
  [@b54]^b^      335/668                                        CC             \-            \-            \-                                            OR 3.7                                   \-        \-
  [@b199]        131/313-248[\*](#tf8-2){ref-type="table-fn"}   PC/4 years     \-            \-            \-                                            0.17%. RR 6.6                            \-        \-
  [@b158]^b^     621/406                                        CC             \-            \-            \-                                            OR 3.2[¥](#tf8-4){ref-type="table-fn"}   \-        \-
  [@b215]        846/1212                                       CC             \-            x             x                                             0.15%                                    \-        0.84%

**Abbreviations:** ATIII, antithrombin III deficiency; CC, case-control; FVL, factor V Leiden; MPG, mutation of the prothrombin gene; OR, odds ratio; PC, prospective cohort; PC, protein C; PS, protein S; RC, retrospective cohort; RR, relative risk; TC, transversal cohort.

**Notes:** Patients/asymptomatic holders

Patients/asymptomatic holders-controls

Not a risk factor

Not a risk factor for age \>70 years (OR 0.8; 95% CI 0.4--1.7): Thrombophilias evaluated in combination.

Hyperhomocysteinemia (HHC) has been considered a risk factor not only for arterial disease, but also for venous thrombosis. In 1998, den Heijer and colleagues (1998) reviewed 8 case-control studies in a meta-analysis, and showed correlations between fasting HHC and VTE (OR 2.5; 95% CI 1.8--3.5), and methionine-induced HHC and VTE (OR 2.6; 95% CI 1.6--4.4). Furthermore, the risk seems to be even higher in patients older than 60 years (OR 4.4; 95% CI 1.9--9.8) (Ray 1998). Thus, HHC should be considered a risk factor for VTE (EVIDENCE A).

Other risk factors
------------------

Although some conditions, such as, systemic arterial hypertension, diabetes mellitus and tobacco smoking are cited occasionally as potential risk factors for VTE, we did not find enough evidence to justify their inclusion on the list of factors that predispose hospitalized medical patients to the development of venous thrombosis.

### VTE prophylaxis

Compared with surgical patients, there are few studies evaluating VTE prophylaxis in medical patients. Besides, the great range of clinical conditions and variations in individual characteristics make it difficult to create a single recommendation suitable for all patients or even define if there is superiority of one type or one particular regimen of heparin over the others. [Table 9](#tbl9){ref-type="table"} shows the evidence-based recommendations for prophylaxis, as they are found in the literature, for specific conditions and not for medical patients as a group. [Table 9](#tbl9){ref-type="table"} also shows that, in most studies, the regimens of heparin involve high prophylactic doses: LDUH 5.000 IU every 8 hours, enoxaparin 40 mg daily, dalteparin 5.000 IU daily or nadroparin also in high doses (3.800 IU for patients with less than 70 kg and 5.700 IU for those weighing 70 kg or more). All these studies have proved the efficacy of these regimens in decreasing the incidence of VTE. This leads to the initial conclusion that medical patients benefit from high prophylactic doses of heparin. Therefore, these high prophylactic doses are the ones recommended (GRADE I) for most hospitalized medical patients on the algorithm ([Figure 1](#fig1){ref-type="fig"}). Only a few studies, usually with very few patients and some methodological flaws ([@b73]; [@b115]; [@b187]; [@b116]) have shown that low prophylactic doses of heparin have efficacy. Besides, in the MEDENOX study ([@b187]) that compared the high (40 mg) and low (20 mg) prophylactic doses of enoxaparin with placebo, only the higher dose reduced significantly the incidence of VTE. In the groups receiving 20 mg of enoxaparin, the incidence of DVT detected by phlebography was similar to that of the placebo group (14.5% vs 15.0%). Finally, a large randomized placebo-controlled trial, published after this review had been concluded ([@b33]) showed that fondaparinux, a synthetic, selective inhibitor of factor Xa, at a dose of 2.5 mg/day subcutaneously for 14 days was also effective for the prevention of VTE in older acutely ill medical patients.

![Algorithm for VTE prevention in hospitalized medical patients.](vhrm0304-533-01){#fig1}

###### 

Evidence-based recommendations for VTE prophylaxis in patients with specific medical conditions [Ψ](#tf9-7){ref-type="table-fn"}

  Condition                                                                                Method                                  Evidence                              Recommendation                                            Dose
  ---------------------------------------------------------------------------------------- --------------------------------------- ------------------------------------- --------------------------------------------------------- --------------------------------------------------------------------------------------------
  Previous VTE +                                                                           LDUH                                    C[1](#tf9-8){ref-type="table-fn"}     I                                                         5.000 IU 8--8h
  risky condition                                                                          LMWH                                    C[2](#tf9-9){ref-type="table-fn"}     I                                                         Dalteparin (5.000 IU/day) or enoxaparin (40 mg/day)
  Chronic venous insufficiency/varices                                                     Enoxaparin                              A[3](#tf9-10){ref-type="table-fn"}    IIa                                                       40 mg/day
  Dalteparin                                                                               A[4](#tf9-11){ref-type="table-fn"}      IIa                                   5.000 IU/day                                              
  Obesity + risky conditions                                                               Enoxaparin                              B[5](#tf9-12){ref-type="table-fn"}    IIa                                                       40 mg/day
  Dalteparin                                                                               A[6](#tf9-13){ref-type="table-fn"}      IIa                                   5.000 IU/day                                              
  Thrombophilias + risky conditions                                                        LDUH, LMWH or Warfarin                  B[7](#tf9-14){ref-type="table-fn"}    I                                                         5.000 IU 8+8h or dalteparin (5.000 IU/day) or enoxaparin (40 mg/day) or warfarin (RNI 2+3)
  HRT/HC + risky conditions                                                                LDUH                                    C[8](#tf9-15){ref-type="table-fn"}    I                                                         5.000 IU 8--8h
  LMWH                                                                                     C[9](#tf9-16){ref-type="table-fn"}      I                                     Dalteparin (5.000 IU/day) or enoxaparin (40 mg/day)       
  CHF                                                                                      LDUH                                    A[10](#tf9-17){ref-type="table-fn"}   I                                                         5.000 IU 8--8h
  Enoxaparin                                                                               A[11](#tf9-18){ref-type="table-fn"}     I                                     40 mg/day                                                 
  Dalteparin                                                                               A[12](#tf9-19){ref-type="table-fn"}     I                                     5.000 IU/day                                              
  AMI                                                                                      LDUH                                    B[13](#tf9-20){ref-type="table-fn"}   I                                                         5.000 IU 12--12h or full dose
  Dalteparin                                                                               B[14](#tf9-21){ref-type="table-fn"}     I                                     120 IU/Kg                                                 
  Ambulation                                                                               B[15](#tf9-22){ref-type="table-fn"}     IIa                                   --                                                        
  ES                                                                                       B[16](#tf9-23){ref-type="table-fn"}     IIa                                   --                                                        
  Ischemic CVA                                                                             LDUH[\*](#tf9-2){ref-type="table-fn"}   A[17](#tf9-26){ref-type="table-fn"}   I or III                                                  5.000 IU 8--8h or 12--12h
  LMWH[\*](#tf9-2){ref-type="table-fn"}                                                    B[18](#tf9-25){ref-type="table-fn"}     I or III                              Dalteparin (2.500 IU 12--12h) or enoxaparin (40 mg/day)   
  ES[\* \*](#tf9-3){ref-type="table-fn"}                                                   B[19](#tf9-26){ref-type="table-fn"}     IIb                                   --                                                        
  IPC + LDUH[\* \* \*](#tf9-4){ref-type="table-fn"}                                        B[20](#tf9-27){ref-type="table-fn"}     IIb                                   IPC + HNF 5.000 IU 12--12h                                
  Hemorrhagic CVA                                                                          INITIAL phase:                                                                                                                          
  LDUH or LMWH                                                                             B[21](#tf9-28){ref-type="table-fn"}     III                                   CONTRAINDICATED                                           
  ES/IPC[\* \*](#tf9-3){ref-type="table-fn"} and [\* \* \*](#tf9-4){ref-type="table-fn"}   B[22](#tf9-29){ref-type="table-fn"}     IIb                                   --                                                        
  LATE phase:                                                                              C[23](#tf9-30){ref-type="table-fn"}     IIb                                   --                                                        
  LDUH or LMWH[\* \* \* \*](#tf9-5){ref-type="table-fn"}                                                                                                                                                                           
  Acute rheumatological diseases/IBD                                                       Enoxaparin                              B[24](#tf9-31){ref-type="table-fn"}   I                                                         40 mg/day
  Dalteparin                                                                               A[25](#tf9-32){ref-type="table-fn"}     I                                     5.000 IU/day                                              
  Severe respiratory diseases                                                              LDUH                                    A[26](#tf9-33){ref-type="table-fn"}   I                                                         5.000 IU 8--8h
  Enoxaparin                                                                               A[27](#tf9-34){ref-type="table-fn"}     I                                     40 mg/day                                                 
  Dalteparin                                                                               A[28](#tf9-35){ref-type="table-fn"}     I                                     5.000 IU/day                                              
  ES                                                                                       B[29](#tf9-36){ref-type="table-fn"}     IIa                                   Continuous                                                
  Infections                                                                               LDUH                                    B[30](#tf9-37){ref-type="table-fn"}   I                                                         5.000 IU 8--8h or 12--12h
  Enoxaparin                                                                               A[31](#tf9-38){ref-type="table-fn"}     I                                     40 mg/day                                                 
  Dalteparin                                                                               A[32](#tf9-39){ref-type="table-fn"}     I                                     5.000 IU/day                                              
  Nephrotic syndrome                                                                       Enoxaparin                              B[33](#tf9-40){ref-type="table-fn"}   I                                                         40 mg/day
  Neoplasias                                                                               Enoxaparin                              B[34](#tf9-41){ref-type="table-fn"}   IIa                                                       40 mg/day
  Admission to ICU                                                                         LDUH                                    B[35](#tf9-42){ref-type="table-fn"}   I                                                         5.000 IU 12--12h
  Enoxaparin                                                                               B[36](#tf9-43){ref-type="table-fn"}     I                                     40 mg/day                                                 
  Nadroparin                                                                               B[37](#tf9-44){ref-type="table-fn"}     I                                     3.800 IU or 5.700 IU/day                                  
  ES/IPC[\* \*](#tf9-3){ref-type="table-fn"} and [\* \* \*](#tf9-4){ref-type="table-fn"}   B[38](#tf9-45){ref-type="table-fn"}     IIa                                   --                                                        
  CVC for PN                                                                               LDUH                                    A[39](#tf9-46){ref-type="table-fn"}   IIb                                                       5.000 IU 6--6h or 12--12h SC, or 1U/mL -- 3 U/mL in PN
  CVC in cancer                                                                            Dalteparin                              A[40](#tf9-47){ref-type="table-fn"}   I                                                         2.500 IU/day
  patients[†](#tf9-1){ref-type="table-fn"}                                                 Nadroparin                              B[41](#tf9-48){ref-type="table-fn"}   IIa                                                       2.850UI a 7.600 IU/day
  Warfarin[\* \* \* \* \*](#tf9-6){ref-type="table-fn"}                                    B[41](#tf9-48){ref-type="table-fn"}     IIb                                   1mg/day                                                   

**Notes:** §Nadroparin and LDUH were equivalent, but more patients in the nadroparin group died (2.8% vs 1.2%; p = 0.02)

In cancer patients, hospitalized and with reduced mobility, prevail the recommendations related to the clinical situation not to the catheter.

In patients with a well defined deficit with reduced mobility, and cerebral hemorrhage excluded with CT or NMR -- RECOMMENDATION I. RECOMMENDATION III for systematic use in all patients due to the increased risk of bleeding.

Lower efficacy in very high-risk patients.

Attention to the IPC contraindications, like arterial peripheral disease.

Prophylaxis may be considered after 10 days of the onset, provided patient is clinically and radiologically stable.

Patients with high risk for bleeding must be excluded (liver metastasis or use of fluoracil and derivates).

High prophylactic doses: LDUH 5.000 IU every 8 hours, enoxaparin 40 mg daily, dalteparin 5.000 IU daily or nadroparin (3.800 IU for \<70 kg and 5.700 IU ≥70 kg) daily are the ones recommended (GRADE I) for most hospitalized edical patients on the algorithm.

**Abbreviations:** CHF congestive heart failure; AMI, acute myocardial infarction; CVA, cerebral vascular accident; ARD, active rheumatological disease; IBD, inflammatory bowel disease; ICU, intensive care unit; VTE, venous thromboembolism; LMWH, low molecular weigh heparin, LDUH, low dose unfractionated heparin; ES, elastic stockings; IPC, intermittent pneumatic compression; CVC, central venous catheter and PN, parenteral nutrition.
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Four important RCTs evaluated VTE prophylaxis in medical patients as a group ([@b73]; [@b115]; [@b187]; [@b116]). Together they included 7,735 patients, with average ages of 68 to 74 years-old. Diseases and conditions listed as risk factors are presented on [Table 10](#tbl10){ref-type="table"}. The most common reasons for admission were CHF, respiratory insufficiency and infection. The most common risk factors were obesity, varices, cancer, active rheumatologic disorders and previous VTE. Enoxaparin ([@b115]; [@b187]), dalteparin ([@b116]), nadroparin ([@b73]), and LDUH ([@b73]; [@b115]) were used in these studies. [@b73] compared nadroparin 3.600 IU with LDUH 5.000 IU, every 8 hours in 1,968 medical patients. Although there were no differences on the efficacy of prophylaxis or on the rate of bleeding, more patients in the nadroparin group died (2.8% vs 1.2% in LDUH group, p = 0.02). However, [@b56] evaluated nadroparin as VTE prophylaxis in 223 patients with acute exacerbation of COPD requiring mechanical ventilation and demonstrated the efficacy of this LMWH against placebo, without increased bleeding or death rates.

###### 

The most common diseases and risk factors for VTE found in four large RCTs about efficacy of prophylaxis in hospitalized medical patients[1](#tf10-1){ref-type="table-fn"}--[4](#tf10-4){ref-type="table-fn"}

  Disease/Risk factor            \%
  ------------------------------ ----------
  Congestive heart failure       30--52
  Respiratory disease            24--53
  Infection                      20--54
  Obesity                        27--53
  Varices                        22--27
  Cancer                         4.6--20
  Active rheumatologic disease   7.6--11
  Past history of VTE            3.4--8.4
  Estrogen therapy               1.4--1.8
  Bowel inflammatory disease     0.5--0.8

Notes: [@b73]

[@b115]

[@b187]

[@b116].

Another important issue is how long the prophylaxis should be maintained. It is common belief among physicians that as soon as the patient is able to ambulate, the risk is over and prophylaxis could be discontinued. However, there is no support in the literature for this, and in all studies that included hospitalized medical patients with risk factors to VTE, prophylaxis was maintained for at least 6 to 14 days ([@b73]; [@b115]; [@b187]; [@b106]; [@b116]). In the PREVENT ([@b116]) study, authors are specific about the point that all patients received the medication (dalteparin or placebo) for 14 days, even if they were discharged earlier. Besides, in the MEDENOX ([@b73]; [@b115]; [@b187]; [@b116]) and in the PREVENT ([@b116]) studies, patients were reevaluated several weeks after prophylaxis was finished, and symptomatic VTE episodes were detected. We have not found any studies testing prophylaxis for less than 6 days. Until new data is available, it's recommended that VTE prophylaxis be maintained for at least 6 to 14 days. There is only one study that we are aware of---the EXCLAIM study (Extended Prophylaxis for Venous Thromboembolism in Acutely Ill Medical Patients with Prolonged Immobilization)---that has evaluated the extension of prophylaxis beyond 14 days in medical patients. The preliminary results of this study were recently presented at the XXIth Congress of the International Society on Thrombosis and Haemostatis and suggest the extension of VTE prophylaxis with enoxaparin 40 mg/day for an additional 28 days, is beneficial for acutely ill medical patients that remain with severely impaired mobility and for those with moderate impairment of mobility plus ≥75 years-old, cancer, or history of VTE. The final manuscript has not yet been published.

Some conditions represent contraindications to heparin use and must have their risk weighed against the potential benefit of the prophylaxis. Active bleeding, allergies, and previous type II heparin induced thrombocytopenia are absolute contraindications; thrombocytopenia for other reasons, coagulopathies, recent surgeries, specially cranial and ocular, lumbar puncture, uncontrolled hypertension, active pepticulcer without bleeding, and renal failure with clearance lower than 30 mL/min are also considered contraindications ([@b116]; [@b187]). In patients with mild to moderate renal failure, LDUH is preferred over LMWH for VTE prophylaxis in medical patients, based on level C of evidence (Class IIa). If LMWH are chosen for patients with renal insufficiency, the measurement of anti-Xa activity is recommended to adjust LMWH doses ([@b86]).

Conclusion
==========

In summary, VTE prophylaxis is recommended for acutely ill, hospitalized medical patients, age 40 years or older, with reduced mobility and at least one additional risk factor for VTE, as suggested in the algorithm below ([Figure 1](#fig1){ref-type="fig"}). Patients younger than 40 years of age, but presenting with important risk factors, may benefit from prophylaxis. When the algorithm for risk assessment indicates that VTE prophylaxis is recommended, LMWH once a day (enoxaparin 40 mg, dalteparin 5.000 IU, nadroparin 3.800 IU if ≤70 Kg or 5.700 IU if \>70 Kg) or LDUH 5.000 UI SC every 8 h should be used and maintained for 6 to 14 days, even if the patient resumes ambulation or has early discharge. For patients older than 60 years, fondaparinux 2.5 mg once a day is also an option. If there is contraindication for pharmacological prophylaxis, mechanical methods of prophylaxis may be considered. However, all patients must be frequently reevaluated for the appearance of new indications or contraindications for prophylaxis during the hospitalization.

Key points
==========

-   Hospitalized medical patients have increased risk of thromboembolic complications.

-   Our multidisciplinary group created an easy-to-use algorithm to facilitate the implementation of evidence-based recommendations for prophylaxis of hospitalized medical patients into practice.

-   In the absence of contraindications, hospitalized medical patients that are older than 40 years of age, have reduced mobility and at least one additional risk factor for VTE should be given high prophylactic doses of LDUH or LMWH for 6 to 14 days.
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